Coherus Oncology, Inc. CHRS
As ofNov 20, 2026, 3:48 PM EST
- YTD
- -73.82%
- 1 year
- -66.21%
5D -0.1461 (-23.39%)
- Market cap
- 57.44M
- Revenue (ttm)
- 304.34M
- Profit margin
- -0.15%
- EPS (ttm)
- -1.12
- Shares out
- 115.21M
- Forward P/E
- -5.30
- YTD return
- -73.82%
- 1-year return
- -66.21%
- 50-day average
- 1.10
- Volume
- 2.21M
- Avg volume
- 1.78M
- Open
- 0.3868
- Previous close
- 0.3871
- Day's range
- 0.364 – 0.4084
- 52-week range
- 0.364 – 2.62
- Beta
- 0.69
- Analysts
- Buy
- Price target
- 5.90 (+1487.3%)
Key statistics
- 200-day average
- 1.56
- Enterprise value
- 347.31M
- Price / sales
- 0.54
- Revenue growth
- -5.10%
- Free cash flow
- 42.63M
- Total cash
- 97.69M
- Total debt
- 269.88M
- Short % of float
- 31.11%
Fundamental scorecard
5 of 25 checks passed on CHRS’s reported financials
5of 25 checks passed
- Value 1 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2024 | Sep 1, 2024 | -0.10 | -0.01 | +0.09 | +90.00% |
| Aug 8, 2024 | Jun 1, 2024 | -0.21 | -0.14 | +0.07 | +33.33% |
| May 9, 2024 | Mar 1, 2024 | -0.05 | -0.32 | -0.27 | -540.00% |
| Mar 13, 2024 | Dec 1, 2023 | -0.21 | -0.62 | -0.41 | -195.24% |
| Nov 6, 2023 | Sep 1, 2023 | -0.21 | -0.27 | -0.06 | -28.57% |
| Aug 2, 2023 | Jun 1, 2023 | -0.52 | -0.38 | +0.14 | +26.92% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 5, 2024 | Baird | main | Outperform | Outperform |
| Dec 4, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 8, 2024 | Baird | main | Outperform | Outperform |
| Nov 7, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 16, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 16, 2024 | UBS | down | Buy | Neutral |
About Coherus Oncology, Inc.
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- coherus.com
News
Here's Why Coherus Oncology (CHRS) Is a Great 'Buy the Bottom' Stock Now
Down 49.7% in 4 Weeks, Here's Why Coherus Oncology (CHRS) Looks Ripe for a Turnaround
12 Health Care Stocks Moving In Tuesday's Intraday Session Guggenheim Maintains Buy on Coherus Oncology, Lowers Price Target to $8
Coherus BioSciences Q3 2026 Earnings Call Transcript Coherus BioSciences Q3 Adj. EPS $(0.20) Beats $(0.22) Estimate, Sales $14.274M Miss $16.005M Estimate
12 Health Care Stocks Moving In Thursday's Intraday Session HC Wainwright & Co. Assumes Coherus Oncology at Buy, Announces Price Target of $7
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Your note
Sign in to keep a note on CHRS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| LANFEAR DENNIS M | Chief Executive Officer | Conversion of Exercise of derivative security | Nov 21, 2023 | 1,251,340 |
| MCMICHAEL BRYAN J | Officer | Stock Award(Grant) | Jan 19, 2023 | 26,386 |
| STILWELL MCDAVID H. | Chief Financial Officer | Stock Award(Grant) | Jan 19, 2023 | 104,243 |
| VEXLER VLADIMIR | Officer | Stock Award(Grant) | Jan 19, 2023 | 131,323 |
| WAHLSTROM MATS | Director | Stock Gift | Feb 8, 2024 | 99,988 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 10.37% | 11,951,953 | 17.09M | Sep 29, 2024 |
| Vanguard Group Inc | 9.82% | 11,310,682 | 16.17M | Sep 29, 2024 |
| Rubric Capital Management LP | 9.03% | 10,400,000 | 14.87M | Sep 29, 2024 |
| Kohlberg Kravis Roberts & Co. L.P. | 2.64% | 3,036,076 | 4.34M | Sep 29, 2024 |
| Citadel Advisors Llc | 2.48% | 2,857,208 | 4.09M | Sep 29, 2024 |
| Geode Capital Management, LLC | 2.23% | 2,565,145 | 3.67M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.98% | 3,434,698 | 4.91M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.47% | 2,848,045 | 4.07M | Oct 30, 2024 |
| Vanguard Strategic Equity Fund | 1.48% | 1,705,512 | 2.44M | Sep 29, 2024 |
| Vanguard Explorer Fund, Inc. | 1.47% | 1,693,303 | 2.42M | Jul 30, 2024 |
| Vanguard Extended Market Index Fund | 1.20% | 1,386,562 | 1.98M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.98% | 1,129,893 | 1.62M | Aug 30, 2024 |
